IRLAB to initiate a study of IRL757 in Parkinsons’s disease with full financial backing from its development partner MSRD

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY.Gothenburg, Sweden, March 27, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its drug candi…
March 27, 2025